NUTX — Nutex Health, Inc.

Nutex Health Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $216.5 million, a 2% increase from $211.8 million in Q1 2025.
• Net Income: $46.8 million, up from $21.2 million in Q1 2025.
• Adjusted EBITDA: $57.6 million, down 21% from $72.8 million in Q1 2025.
• Total Patient Visits: 49,700, a 3.1% increase from 48,300 in Q1 2025.
• Net Long-term Debt: Decreased from $29.2 million to $24.3 million.
• Cash on Hand: Increased to $207.3 million from $185.6 million at year-end 2025.
• Net Cash from Operating Activities: Increased by 48% to $75.5 million from $51 million in Q1 2025.

2. Strategic Updates and Business Highlights

• Share Repurchase Program: Completed a $25 million program and initiated a second $25 million program, indicating management's confidence in the company's value.
• Infrastructure Investments: Focused on scalability and efficiency to support growth in emergency and inpatient volumes.
• New Hospital Development: Board approved direct investment in new hospital facilities, reducing reliance on third-party developers. Three projects in Florida are already underway.
• Population Health Management: Revenue grew 14% to $8.9 million, with a focus on expanding physician networks and value-based contracts.
• Technology Investments: Enhancements in AI and IT to improve patient care and operational efficiency.

3. Forward Guidance and Outlook

• Hospital Openings: On track to open three additional hospitals in Q3 and Q4 2026.
• Revenue Growth: Management expects continued growth in patient volumes and revenue, driven by new service lines and improved reimbursement rates.
• Arbitration Process: Anticipated return to a lower percentage of arbitration costs (24%-26%) in future quarters as collection rates stabilize.

4. Bad News, Challenges, or Points of Concern

• Adjusted EBITDA Decline: Significant drop attributed to timing of IDR expense recognition.
• Milder Flu Season: Contributed to lower-than-expected patient volumes compared to the previous year.
• Increased Operating Costs: Facility operating costs rose significantly, primarily due to arbitration costs and increased patient acuity.
• Competitive Pressures: Ongoing challenges in negotiations with payers, despite recent favorable court rulings.

5. Notable Q&A Insights

• Hospital Development Timeline: New projects typically take 18-24 months to complete, with Nutex planning to finance these developments internally.
• IDR Process: Approximately 50%-60% of claims are submitted through the IDR process, with a collection rate of over 80% on determinations.
• Patient Volume Growth: Recent hospital openings and a milder flu season impacted growth; however, management remains optimistic about future volumes.
• Population Health Strategy: Focus on building physician networks around hospitals to enhance patient awareness and drive volume, with profitability seen in existing IPAs.

This summary encapsulates Nutex Health's performance and strategic direction for Q1 2026, highlighting both achievements and areas of concern as the company navigates its growth trajectory.